KPRX Logo

Kiora Pharmaceuticals, Inc. (KPRX) 

NASDAQ
Market Cap
$10.63M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
244 of 776
Rank in Industry
139 of 433

Largest Insider Buys in Sector

KPRX Stock Price History Chart

KPRX Stock Performance

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid …

Insider Activity of Kiora Pharmaceuticals, Inc.

Over the last 12 months, insiders at Kiora Pharmaceuticals, Inc. have bought $95,206 and sold $0 worth of Kiora Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Kiora Pharmaceuticals, Inc. have bought $2.07M and sold $7.61M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Parsons Erin (director) — $25,669. TYLE PRAVEEN (director) — $19,800. Strem Brian M. (President and CEO) — $14,997.

The last purchase of 1,250 shares for transaction amount of $4,600 was made by Stengone Carmine N. (director) on 2024‑09‑11.

List of Insider Buy and Sell Transactions, Kiora Pharmaceuticals, Inc.

2024-09-11Purchasedirector
1,250
0.0442%
$3.68$4,600-1.63%
2024-09-10Purchasedirector
3,000
0.1039%
$3.60$10,800-0.29%
2024-08-19Purchasedirector
5,000
0.165%
$3.96$19,800-11.63%
2024-08-19Purchasedirector
1,250
0.0402%
$3.86$4,825-11.63%
2024-08-14PurchaseCFO
2,000
0.0667%
$3.21$6,4200.00%
2024-06-14PurchaseChief Development Officer
1,431
0.0556%
$5.29$7,570-31.72%
2024-06-14PurchaseEVP Finance
100
0.0039%
$5.25$525-31.72%
2024-06-13PurchasePresident and CEO
3,000
0.1101%
$5.00$14,997-24.38%
2024-06-13Purchasedirector
5,260
0.1885%
$4.88$25,669-24.38%
2021-11-18PurchasePresident and CEO
17,853
0.1764%
$1.41$25,173-68.88%
2021-08-02Sale10 percent owner
192,775
1.8717%
$2.40$463,046-69.80%
2021-07-30Sale10 percent owner
68,188
0.7096%
$2.69$183,562-70.83%
2021-07-29Sale
400,000
4.0311%
$3.00$1.2M-74.57%
2021-07-28Sale
375,443
3.7408%
$3.28$1.23M-76.79%
2021-07-27Sale
2.38M
31.3018%
$5.09$12.11M-79.90%
2021-01-06Purchase
1.53M
21.542%
$5.22$8M-32.02%
2020-02-10Purchase
12,000
0.2683%
$6.04$72,480-18.43%
2020-02-06Purchase
11,000
0.2463%
$6.18$67,980-20.16%
2019-12-06Saledirector
1,961
0.0619%
$6.93$13,590-27.54%
2019-11-12Saledirector
2,001
0.06%
$4.29$8,584+12.00%

Insider Historical Profitability

<0.0001%
Strem Brian M.President and CEO
14531
0.4892%
$3.5820<0.0001%
Tosca MelissaCFO
13599
0.4578%
$3.5820
Daniels Eric JosephChief Development Officer
11222
0.3778%
$3.5810
Parsons Erindirector
5260
0.1771%
$3.5810
TYLE PRAVEENdirector
5014
0.1688%
$3.5810

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.